NRSN - התחייבויות לטווח ארוך להון NeuroSense Therapeutics Ltd

Alon Ben-Nun's team is currently optimizing clinical trials while maintaining shareholder confidence. NeuroSense Therapeutics (NRSN) relies on patent-protected synergistic platforms to combat ALS and PLP. The global scaling potential of its drugs ensures high profitability. The long-term debt-to-equity ratio demonstrates financial stability, where the value of 0.00 reflects this status of leverage dependency.

Investors evaluate NeuroSense Therapeutics (NRSN) through the lens of its dominance in CNS therapy. This ratio compares liabilities with a maturity of over one year to equity to analyze financial stability. The history of long-term debt-to-equity reflects the balance between leverage and asset protection. A decrease in this metric minimizes risks during the development of unique PrimeC capsules. Low demand elasticity allows the company to manage its borrowings effectively.